2017;136:e137 61. 9.2.2. Heart Failure With Preserved Ejection Fraction S9.2.2-1. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34 42. S9.2.2-2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline forthemanagementofheartfailure:areportoftheAmericanCollege of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. S9.2.2-3. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol. 1997;80:207 9. S9.2.2-4. vanVeldhuisen DJ, Cohen-SolalA, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150 8. S9.2.2-5. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejec- tion fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777 81. S9.2.2-6. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456 67. S9.2.2-7. Aronow WS, Ahn C, Kronzon I. Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest. 1998;113:867 9. S9.2.2-8. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of con- gestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611 2; A9. S9.2.2-9. Vasan RS, Larson MG, Benjamin EJ, et al. 